Table 3.
Pharmacotherapy with carbamazepine in the study population depending on selected clinical parameters (median (lower quartile–upper quartile) or number (percent)).
| Study Feature (n = 682) |
The Daily Dose of Carbamazepine (mg) | p | The Daily Dose of Carbamazepine Per Kilogram of Body Weight (mg) | p |
|---|---|---|---|---|
| Sex | 0.3593 | 0.0891 | ||
| Men | 600 (400–800) | 11.43 (8.57–15.38) | ||
| Women | 600 (400–800) | 12.1 (9.52–16.0) | ||
| Age | <0.00001 | <0.00001 | ||
| 3–17(years) | 450 (300–600) | 13.64 (10.26–17.86) | ||
| ≥18 (years) | 800 (600–900) | 10.43 (8.00–13.33) | ||
| Carbamazepine below the therapeutic level (<4 µg/mL) |
400 (300–600) | <0.00001 | 9.92 (6.78–12.50) | <0.00001 |
| The therapeutic level of carbamazepine (4–12 µg/mL) |
600 (450–800) | 12.86 (9.68–16.67) | ||
| Carbamazepine above the therapeutic level (≥12µg/mL) |
850 (600–1000) | 12.50 (10.0–18.46) |